LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

Search

BioMarin Pharmaceutical Inc

Abierto

SectorSalud

54.56 0.63

Resumen

Variación precio

24h

Actual

Mínimo

53.56

Máximo

54.96

Métricas clave

By Trading Economics

Ingresos

241M

426M

Ventas

80M

825M

P/B

Media del Sector

15.958

35.664

BPA

1.44

Margen de beneficio

51.637

Empleados

3,040

EBITDA

95M

319M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+85.53% upside

Dividendos

By Dow Jones

Próximas Ganancias

28 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-1.2B

10B

Apertura anterior

53.93

Cierre anterior

54.56

Noticias sobre sentimiento de mercado

By Acuity

32%

68%

109 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 sept 2025, 17:03 UTC

Principales Movimientos del Mercado

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sept 2025, 16:49 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

GD Culture Shares Drop After Deal for Pallas Capital

16 sept 2025, 16:11 UTC

Principales Movimientos del Mercado

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sept 2025, 23:40 UTC

Charlas de Mercado

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sept 2025, 23:34 UTC

Charlas de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sept 2025, 23:20 UTC

Charlas de Mercado

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sept 2025, 21:10 UTC

Adquisiciones, fusiones, absorciones

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sept 2025, 20:51 UTC

Charlas de Mercado

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sept 2025, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

16 sept 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

16 sept 2025, 20:25 UTC

Ganancias

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sept 2025, 20:24 UTC

Ganancias

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sept 2025, 19:19 UTC

Charlas de Mercado

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sept 2025, 18:52 UTC

Charlas de Mercado

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sept 2025, 18:44 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 sept 2025, 18:44 UTC

Charlas de Mercado

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sept 2025, 18:40 UTC

Adquisiciones, fusiones, absorciones

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sept 2025, 18:38 UTC

Charlas de Mercado

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sept 2025, 18:19 UTC

Charlas de Mercado

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sept 2025, 18:01 UTC

Charlas de Mercado

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sept 2025, 17:34 UTC

Charlas de Mercado

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sept 2025, 16:53 UTC

Ganancias

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sept 2025, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

16 sept 2025, 16:15 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Commodities Roundup: Market Talk

16 sept 2025, 16:09 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Energy Roundup: Market Talk

16 sept 2025, 16:09 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sept 2025, 15:35 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 sept 2025, 15:35 UTC

Charlas de Mercado

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sept 2025, 15:22 UTC

Charlas de Mercado

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sept 2025, 15:21 UTC

Charlas de Mercado

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparación entre iguales

Cambio de precio

BioMarin Pharmaceutical Inc Esperado

Precio Objetivo

By TipRanks

85.53% repunte

Estimación a 12 meses

Media 98.59 USD  85.53%

Máximo 122 USD

Mínimo 60 USD

De acuerdo con 24 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioMarin Pharmaceutical Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

24 ratings

20

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

59.405 / 62.19Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

109 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat